Gene secrets could explain why heart drug works for some, not others

NCT ID NCT07408427

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find out why the heart medication mavacamten works better for some people with hypertrophic cardiomyopathy (a condition where the heart muscle is too thick) than for others. Researchers will look at participants' genes, including the specific gene causing their condition and a gene called CYP2C19 that affects how the body processes drugs. The goal is to predict who will benefit most from the medication, leading to more personalized treatment. About 140 adults with this condition will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Manchester Centre for Genomic Medicine (MCGM)

    Multiple Locations, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact